🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Neutrophil-activating therapy for the treatment of cancer dlvr.it/SjQvVn

Online Now: Metabolic programming and immune suppression in the tumor microenvironment dlvr.it/SjZS9M

Our latest paper providing first proof of principle. Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes ashpublications.org/bloodadvances/…

Many Congratulations to Moffitt Hematology/Oncology Fellowship fellows Luis E. Aguirre, MD and James Yu for getting selected for Conquer Cancer, the ASCO Foundation ASCO merit award! Can't wait to see you present your study results at #ASCO23 !!

It was fun taking part in this debate session w Luis E. Aguirre, MD and great talk on #MDSsm response criteria by Amer Zeidan MBBS,MHS ‏عامر زيدان and panel discussion MD Education Rami komrokji Moffitt Hematology/Oncology Fellowship Moffitt Cancer Center #MPNMDS US focus meeting 23

Congratulations on representing Moffitt Hematology/Oncology Fellowship at the #MDSMPN US focus meeting debate stage! 👏👏

Our latest paper validating IPSS-M in one of the largest cohorts published in leukemia journal. Kudos to super fellow Luis Aguirre and the whole MDS team ⁦Luis E. Aguirre, MD⁩ ⁦Moffitt Cancer Center⁩ ⁦Moffitt Research⁩ ⁦Eric Padron MD⁩ nature.com/articles/s4137…

#HappeningNow | Dr. Luis Aguirre (Luis E. Aguirre, MD) presents on the “Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes” at the #MoffittScientifcSymposium.

At the #MoffittScientifcSymposium, Dr. Luis Aguirre (Luis E. Aguirre, MD) discussed “Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes."

Honored I gave the Carol & John Bennett lecture marking 20 yr out of my training at UR & being recipient of their inaugural research award. A special treaty by Dr Bennett staying at their home. A legend and amazing mentor for whom I ll ever be in debt Wilmot Cancer Institute Moffitt Cancer Center

#ASCO2023 | Moffitt's Dr. Rami Komrokjii discusses the results of a phase 3 clinical trial of Imetlestat, a telomerase inhibitor used for treating for both MDS and myelofibrosis. #MoffittASCO23 ASCO

Join Dr. Luis Aguirre (Luis E. Aguirre, MD) for a poster discussion on refining risk stratification in CMML at #ASCO23. ⏰: 6/5 from 11:30-1 p.m. CDT 📍: E450 Learn more ➡️ bit.ly/42k0OmC #MoffittASCO23 ASCO

Dr. Luis Aguirre (Luis E. Aguirre, MD) joined President and CEO Dr. Patrick Hwu at #ASCO23 for a discussion on refining risk stratification in CMML. Learn more ➡️ bit.ly/42k0OmC #MoffittASCO23 ASCO

Ghida Talal Amer Zeidan MBBS,MHS ‏عامر زيدان Yale Cancer Center Yale School of Medicine First and senior author are Jordanians 🙃 I told Amer to have the Jordanian Flag next to his name and mine .. we appreciate your endless support your highness .. proud moment for amer and I to lead development of next treatment in MDS

LIVE from #ASCO23: Dr. Luis Aguirre’s (Luis E. Aguirre, MD) abstract on “Refining risk stratification in CMML: A comprehensive assessment of the IPSS-M and other molecularly informed models” is presented. Learn more ➡️ meetings.asco.org/abstracts-pres… #ASCO23 #MoffittASCO23 ASCO

Such an honor to witness the Graduate Medical Education graduation last night Moffitt Cancer Center! Congratulations to the more than 50 graduating fellows.

❓ What's the latest in lower-risk myelodysplastic syndrome (LR-MDS) management? Join as Dr. Rami komrokji summarizes the latest data. #CME #MedEd #MedTwitter 🖥️ Take our activity here: ms.spr.ly/6019gaDGL

Promising strides in #leukemia treatment from Jeffrey Lancet (Moffitt Cancer Center)! Early findings from COVALENT-101 on BMF-219, a covalent menin inhibitor, show encouraging results in patients with relapsed/refractory #AcuteLeukemia #ASH23 ASH #Leusm

Our recent manuscript addressing Triple-Negative Myelofibrosis clinical-lymphoma-myeloma-leukemia.com/article/S2152-… great work by Luis E. Aguirre, MD Andrew Kuykendall MD Moffitt Cancer Center

I am so honored to be part of this journey as a senior clinical investigator and having presented the data to the ODAC FDA committee to get Imetelstat approved to hopefully help many of our MDS patients. ⁦⁦⁦Moffitt Cancer Center⁩ ir.geron.com/investors/pres…